跳至主要内容
临床试验/NCT00578929
NCT00578929已完成3 期

Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients

Alcon Research1 个研究点 分布在 1 个国家目标入组 2,388 人开始时间: 2007年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
2,388
试验地点
1
主要终点
Percent Change From Baseline in the Reflective Total Nasal Symptom Score (TNSS)

研究概览

简要总结

A study to demonstrate the superiority of test article nasal spray relative to vehicle nasal spray for the treatment of seasonal allergic rhinitis for a 2 week period in patients aged 6 to 11 years with a history of seasonal allergic rhinitis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
6 Years 至 11 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Male or female; minimum of 6 years of age and less than 12 years
  • 2 year history of seasonal allergic rhinitis

排除标准

  • Concurrent disease that might interfere with the investigation or evaluation of te study medication
  • Confirmed diagnosis of chronic rhinosinusitis within the last year
  • Asthma, with the exception of mild intermittent asthma
  • Anatomical nasal deformity
  • Nasal obstruction
  • Known non-responder to antihistamines for symptoms of Seasonal Allergic Rhinitis (SAR)
  • Chronic or intermittent use of of inhaled, oral, intramuscular intravenous corticosteroids ot topical steroids
  • Ocular disorder other that allergic conjunctivitis

研究组 & 干预措施

Olopatadine 0.6% 1 Spray

Experimental

Olopatadine HCl 0.6% 1 spray per nostril twice daily

干预措施: Olopatadine Hydrochloride Nasal Spray 0.6% (Drug)

Vehicle 1 spray

Placebo Comparator

Vehicle 1 spray per nostril twice daily

干预措施: Vehicle (Drug)

Olopatadine 0.6% 2 sprays

Experimental

Olopatadine HCl 0.6% 2 sprays per nostril twice daily

干预措施: Olopatadine Hydrochloride Nasal Spray 0.6% (Drug)

Vehicle 2 sprays

Placebo Comparator

Vehicle 2 sprays per nostril twice daily

干预措施: Vehicle (Drug)

结局指标

主要结局

Percent Change From Baseline in the Reflective Total Nasal Symptom Score (TNSS)

时间窗: Baseline through 2 weeks after randomization

Total Nasal Symptom Score comprised of scoring each of the following symptoms: runny nose, stuffy nose, itchy nose, and sneezing. Each symptom was scored as a 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The 4 individual symptom scores were then added together for a total nasal symptom score. The percent change from baseline was defined as the average of the morning and evening severity scores for the sum of the assessments of the 4 individual scores averaged across all days.

次要结局

  • Percent Change From Baseline in the Reflective Total Ocular Symptom Score (TOSS)(Baseline through 2 weeks after randomization)

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验